Cytokine is a small protein produced by immune cells, which plays an important role in maintaining physiological immune homeostasis and regulating pathophysiological processes (such as cancer and autoimmune diseases). Cytokines are classified into different subtypes according to the conformation of their receptors, including chemokines, interferons (IFNs), interleukins (ILs), and tumor necrosis factors (TNFs).
In view of their important role in regulating immune response, many pro-inflammatory cytokines have been identified as candidate drugs for the treatment of various cancers. So far, several cytokines including recombinant IL-2, IFNs, and TNFs have been approved for clinical cancer immunotherapy. However, there are some cytokines that control the activity of immune cells and make them beneficial to tumor growth. For example, immunomodulatory cytokines in the tumor microenvironment recruit other immunosuppressive cells and are responsible for the phenotypic and functional transformation of effector immune cells to support the development of tumors. As an indispensable part of tumor immunotherapy, cytokines still have many unsolved problems.
This Research Topic aims to highlight the influence of cytokines on tumor immunotherapy and the development of new biomarkers for tumor immunotherapy based on cytokines. Authors are welcome to submit Original Research and Review articles about the study on the roles of cytokines in tumor immunotherapy and the development of new biomarkers for tumor immunotherapy based on cytokines. Subtopics include but are not limited to:
1)Roles and mechanisms of pro-inflammatory cytokines in cancer immunotherapy;
2)Development of cytokine drugs with high specificity, high selectivity, and longer half-life;
3)Dual mechanism of Interferon-? enhancing or decreasing T cell function in cancer;
4)Multiomics study on the relationship between cytokines or their related genes and the occurrence and development of cancer on the pan-cancer level;
5)Clinical study on the combination of cytokine drugs and other immunotherapy drugs;
6)Mechanism of cytokines on tumor immune microenvironment remodeling;
7)Development of new tumor immunotherapy predictive biomarkers based on cytokines.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Cytokine is a small protein produced by immune cells, which plays an important role in maintaining physiological immune homeostasis and regulating pathophysiological processes (such as cancer and autoimmune diseases). Cytokines are classified into different subtypes according to the conformation of their receptors, including chemokines, interferons (IFNs), interleukins (ILs), and tumor necrosis factors (TNFs).
In view of their important role in regulating immune response, many pro-inflammatory cytokines have been identified as candidate drugs for the treatment of various cancers. So far, several cytokines including recombinant IL-2, IFNs, and TNFs have been approved for clinical cancer immunotherapy. However, there are some cytokines that control the activity of immune cells and make them beneficial to tumor growth. For example, immunomodulatory cytokines in the tumor microenvironment recruit other immunosuppressive cells and are responsible for the phenotypic and functional transformation of effector immune cells to support the development of tumors. As an indispensable part of tumor immunotherapy, cytokines still have many unsolved problems.
This Research Topic aims to highlight the influence of cytokines on tumor immunotherapy and the development of new biomarkers for tumor immunotherapy based on cytokines. Authors are welcome to submit Original Research and Review articles about the study on the roles of cytokines in tumor immunotherapy and the development of new biomarkers for tumor immunotherapy based on cytokines. Subtopics include but are not limited to:
1)Roles and mechanisms of pro-inflammatory cytokines in cancer immunotherapy;
2)Development of cytokine drugs with high specificity, high selectivity, and longer half-life;
3)Dual mechanism of Interferon-? enhancing or decreasing T cell function in cancer;
4)Multiomics study on the relationship between cytokines or their related genes and the occurrence and development of cancer on the pan-cancer level;
5)Clinical study on the combination of cytokine drugs and other immunotherapy drugs;
6)Mechanism of cytokines on tumor immune microenvironment remodeling;
7)Development of new tumor immunotherapy predictive biomarkers based on cytokines.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
